BRIEF—EpimAb and Zhejiang Teruisi ink collaboration

Shanghai’s EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical will join forces on a bispecific antibody program.

Zhejiang Teruisi will gain access to EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) program FIT012/TRS008 to develop it for the Chinese market.

EpimAb retains all commercial rights to the program outside of China and will receive an upfront payment and total success-based milestones of up to $21 million, plus royalties.

The targets for the candidates and further financial details were not disclosed.